Risk level in pregnancy: This medicine is classified as Category C for the 1st and 2nd quarters and D during the 3rd.
There are no published data on the use of this medicine in pregnant women, both cases observations as systematic studies. Experimental studies have shown reproductive toxicity. For this reason, the effect of etoricoxib in persons is unknown.
Other drugs in the same group, which inhibit prostaglandin synthesis, may cause premature closure of the ductus arteriosus during the last quarter, so it can be inferred that also occurs with this substance .
This drug is contraindicated in pregnancy. In the event that this occurs, it should be discontinued immediately.
Etoricoxib is not authorized in the U.S., so the category assignment is done by similarity to other coxibs.
Meaning of category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.